<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4725">
  <stage>Registered</stage>
  <submitdate>1/12/2014</submitdate>
  <approvaldate>1/12/2014</approvaldate>
  <nctid>NCT02305758</nctid>
  <trial_identification>
    <studytitle>Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer</studytitle>
    <scientifictitle>Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-002866-65</secondaryid>
    <secondaryid>M14-217</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Untreated Metastatic Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Veliparib
Treatment: drugs - Placebo

Experimental: Group 1 - Veliparib plus modified FOLFIRI with or without bevacizumab.

Placebo Comparator: Group 2 - Placebo plus FOLFIRI with or without bevacizumab.


Treatment: drugs: Veliparib
Veliparib will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.

Treatment: drugs: Placebo
Placebo will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (PFS) - The number of days from the date the participant is randomized to the date the participant experiences a disease progression event or to the date of death if disease progression is not reached.</outcome>
      <timepoint>Up to 3 years from the first subject dosed.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival - Overall survival is defined as the number of days from the date that the participant was randomized to the date of the participant's death.</outcome>
      <timepoint>Up to 3 years from the first subject dosed.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective Response Rate (ORR) - The proportion of participants with a complete or partial objective response based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.</outcome>
      <timepoint>Up to 3 years from the first subject dosed.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically confirmed metastatic adenocarcinoma of the colon or
             rectum

          -  At least 1 unresectable lesion on a CT (Computerized Tomography) scan that is
             measurable as defined by RECIST, Version 1.1

          -  ECOG (Eastern Cooperative Oncology Group) performance score of 0 or 1

          -  Adequate hematologic, renal and hepatic function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior anti-cancer treatment for metastatic colorectal cancer

          -  Prior exposure to PARP (poly ADP-ribose polymerase) inhibitors

          -  The last course of adjuvant or neoadjuvant chemotherapy must have ended &gt; 12 months
             prior to colorectal cancer recurrence

          -  Any clinically significant and uncontrolled major medical condition

          -  Participant is pregnant or lactating

          -  Any medical condition, which in the opinion of the study Investigator, places the
             participant at an unacceptably high risk for toxicities

          -  For those receiving bevacizumab, standard medical exclusionary conditions apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>2/12/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>131</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>21/09/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sunshine Coast University Hospital /ID# 131792 - Birtinya</hospital>
    <hospital>The Prince of Wales Hospital /ID# 131793 - Randwick</hospital>
    <hospital>Flinders Medical Centre /ID# 131795 - South Australia</hospital>
    <hospital>Southern Medical Day Care Center /ID# 131791 - Wollongong</hospital>
    <postcode>4575 - Birtinya</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>5042 - South Australia</postcode>
    <postcode>2500 - Wollongong</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bonheiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Charleroi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Roeselare</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Cologne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Pecs</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szolnok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Arkhangelsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Pjatigorsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Tomsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>A Coruna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Seville</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dorchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Nottingham</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AbbVie</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study seeks to evaluate the efficacy and tolerability of veliparib in combination with
      FOLFIRI +/- bevacizumab in previously untreated, metastatic adenocarcinoma of the colon or
      rectum. FOLFIRI is a chemotherapy regimen of fluorouracil, leucovorin and irinotecan.

      This is a blinded study such that the Investigator and Subject will be blinded but AbbVie
      will be unblinded.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02305758</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Philip Komarnitsky, MD</name>
      <address>AbbVie</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>